Recent advances in liposome-based targeted cancer therapy

References

• Siegel RL, Miller KD, Wagle NS, et al. Cancer Statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi: 10.3322/caac.21763.
   PubMed Web of Science ®Google Scholar
• Bardania H, Tarvirdipour S, Dorkoosh F. Liposome-targeted delivery for highly potent drugs. Artif Cells Nanomed Biotechnol. 2017;45(8):1478–1489. doi: 10.1080/21691401.2017.1290647.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. doi: 10.3390/pharmaceutics9020012.
   PubMed Web of Science ®Google Scholar
• Charmsaz S, Prencipe M, Kiely M, et al. Innovative technologies changing cancer treatment. Cancers. 2018;10(6):208. doi: 10.3390/cancers10060208.
   PubMed Web of Science ®Google Scholar
• Morales-Cruz M, Delgado Y, Castillo B, et al. Smart targeting to improve cancer therapeutics. Drug Des Devel Ther. 2019;13:3753–3772. doi: 10.2147/DDDT.S219489.
   PubMed Web of Science ®Google Scholar
• Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019;13:961. doi: 10.3332/ecancer.2019.961.
   PubMed Web of Science ®Google Scholar
• Crommelin DJ, Storm G. Liposomes: from the bench to the bed. J Liposome Res. 2003;13(1):33–36. doi: 10.1081/lpr-120017488.
   PubMed Web of Science ®Google Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145–160. doi: 10.1038/nrd1632.
   PubMed Web of Science ®Google Scholar
• Alavi M, Karimi N, Safaei M. Application of various types of liposomes in drug delivery systems. Adv Pharm Bull. 2017;7(1):3–9. doi: 10.15171/apb.2017.002.
   PubMed Web of Science ®Google Scholar
• Alsawaftah N, Pitt WG, Husseini GA. Dual-targeting and stimuli-triggered liposomal drug delivery in cancer treatment. ACS Pharmacol Transl Sci. 2021;4(3):1028–1049. doi: 10.1021/acsptsci.1c00066.
   PubMedGoogle Scholar
• Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–252. doi: 10.1016/s0022-2836(65)80093-6.
   PubMed Web of Science ®Google Scholar
• Deamer DW. From "banghasomes" to liposomes: a memoir of Alec Bangham, 1921–2010. FASEB J. 2010;24(5):1308–1310. doi: 10.1096/fj.10-0503.
   PubMed Web of Science ®Google Scholar
• Laverman P, Boerman OC, Oyen WJ, et al. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev. 1999;37(1-3):225–235. 10.1016/s0169-409x(98)00095-710837737
   PubMed Web of Science ®Google Scholar
• Jain A, Kumari R, Tiwari A, et al. Nanocarrier based advances in drug delivery to tumor: An overview. Curr Drug Targets. 2018;19(13):1498–1518. 10.2174/138945011966618013110582229384060
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi: 10.1186/1556-276X-8-102.
   PubMed Web of Science ®Google Scholar
• Talegaonkar S, Mishra P, Khar R, et al. Vesicular systems: an overview. Indian J Pharm Sci. 2006;68(2):141. doi: 10.4103/0250-474X.25707.
   Google Scholar
• O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449. doi: 10.1093/annonc/mdh097.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85(18):6949–6953. doi: 10.1073/pnas.85.18.6949.
   PubMed Web of Science ®Google Scholar
• Lee JH, Yeo Y. Controlled drug release from pharmaceutical nanocarriers. Chem Eng Sci. 2015;125:75–84. doi: 10.1016/j.ces.2014.08.046.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Drewe J, Krahenbuhl S. Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine. 2008;3(1):21–29.
   PubMed Web of Science ®Google Scholar
• Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1–2):271–284. doi: 10.1016/s0168-3659(99)00248-5.
   PubMed Web of Science ®Google Scholar
• Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63(3):161–169. doi: 10.1016/j.addr.2010.09.003.
   PubMed Web of Science ®Google Scholar
• Yuan DF, Zong TL, Gao HL, et al. Cell penetrating peptide TAT and brain tumor targeting peptide T7 dual modified liposome preparation and in vitro targeting evaluation. Yao Xue Xue Bao. 2015;50(1):104–110.
   PubMedGoogle Scholar
• Zhang Y, Zhai M, Chen Z, et al. Dual-modified liposome codelivery of doxorubicin and vincristine improve targeting and therapeutic efficacy of glioma. Drug Deliv. 2017;24(1):1045–1055. doi: 10.1080/10717544.2017.1344334.
   PubMed Web of Science ®Google Scholar
• Al-Jamal WT, Al-Jamal KT, Bomans PH, et al. Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small. 2008;4(9):1406–1415. doi: 10.1002/smll.200701043.
   PubMed Web of Science ®Google Scholar
• Erdogan S, Torchilin VP. Gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. Methods Mol Biol. 2017;1522:179–192. doi: 10.1007/978-1-4939-6591-5_14.
   PubMedGoogle Scholar
• Portnoy E, Lecht S, Lazarovici P, et al. Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine. 2011;7(4):480–488. doi: 10.1016/j.nano.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Fonslow BR, Stein BD, Webb KJ, et al. Digestion and depletion of abundant proteins improves proteomic coverage. Nat Methods. 2013;10(1):54–56. doi: 10.1038/nmeth.2250.
   PubMed Web of Science ®Google Scholar
• Li S, Goins B, Zhang L, et al. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem. 2012;23(6):1322–1332. doi: 10.1021/bc300175d.
   PubMed Web of Science ®Google Scholar
• Sercombe L, Veerati T, Moheimani F, et al. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286. doi: 10.3389/fphar.2015.00286.
   PubMed Web of Science ®Google Scholar
• Cho H, Stuart JM, Magid R, et al. Theranostic immunoliposomes for osteoarthritis. Nanomedicine. 2014;10(3):619–627. doi: 10.1016/j.nano.2013.09.004.
   PubMed Web of Science ®Google Scholar
• Accardo A, Morelli G. Review peptide-targeted liposomes for selective drug delivery: advantages and problematic issues. Biopolymers. 2015;104(5):462–479. doi: 10.1002/bip.22678.
   PubMed Web of Science ®Google Scholar
• Bazak R, Houri M, Achy SE, et al. Passive targeting of nanoparticles to cancer: a comprehensive review of the literature. Mol Clin Oncol. 2014;2(6):904–908. doi: 10.3892/mco.2014.356.
   PubMedGoogle Scholar
• Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol. 2000;11(8):1029–1033. doi: 10.1023/a:1008365716693.
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet? Drug Discov Today Technol. 2012;9:e71–e174.
   Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci. 2013;48(3):416–427. doi: 10.1016/j.ejps.2012.12.006.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26(1):57–64. doi: 10.1016/j.urolonc.2007.03.015.
   PubMed Web of Science ®Google Scholar
• Kim SK, Huang L. Nanoparticle delivery of a peptide targeting EGFR signaling. J Control Release. 2012;157(2):279–286. doi: 10.1016/j.jconrel.2011.08.014.
   PubMed Web of Science ®Google Scholar
• Lehtinen J, Raki M, Bergstrom KA, et al. Pre-targeting and direct immunotargeting of liposomal drug carriers to ovarian carcinoma. PLOS One. 2012;7(7):e41410. doi: 10.1371/journal.pone.0041410.
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Galappathi K, Mathiesen BS. Tumor interstitial fluid pressure—a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia. 2014;16(7):586–594. doi: 10.1016/j.neo.2014.07.003.
   PubMed Web of Science ®Google Scholar
• Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392–397. doi: 10.1038/sj.bjc.6604483.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, et al. High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–813. doi: 10.1038/nrc1456.
   PubMed Web of Science ®Google Scholar
• Barenholz YC. Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–134. doi: 10.1016/j.jconrel.2012.03.020.
   PubMed Web of Science ®Google Scholar
• Riaz MK, Riaz MA, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review. Int J Mol Sci. 2018;19:195.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release. 2018;277:1–13. doi: 10.1016/j.jconrel.2018.02.040.
   PubMed Web of Science ®Google Scholar
• Nguyen TX, Huang L, Gauthier M, et al. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine. 2016;11(9):1169–1185. doi: 10.2217/nnm.16.9.
   PubMed Web of Science ®Google Scholar
• Yingchoncharoen P, Kalinowski DS, Richardson DR. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come. Pharmacol Rev. 2016;68(3):701–787. doi: 10.1124/pr.115.012070.
   PubMed Web of Science ®Google Scholar
• Egusquiaguirre SP, Igartua M, Hernandez RM, et al. Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research. Clin Transl Oncol. 2012;14(2):83–93. doi: 10.1007/s12094-012-0766-6.
   PubMed Web of Science ®Google Scholar
• Fay F, Scott CJ. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy. 2011;3(3):381–394. doi: 10.2217/imt.11.5.
   PubMed Web of Science ®Google Scholar
• Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: a step in the right direction. Chem Sci. 2017;8(1):63–77. doi: 10.1039/c6sc02403c.
   PubMed Web of Science ®Google Scholar
• Rigon RB, Oyafuso MH, Fujimura AT, et al. Nanotechnology-based drug delivery systems for melanoma antitumoral therapy: a review. Biomed Res Int. 2015;2015:841817–841822. doi: 10.1155/2015/841817.
   PubMed Web of Science ®Google Scholar
• Spicer CD, Jumeaux C, Gupta B, et al. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. Chem Soc Rev. 2018;47(10):3574–3620. doi: 10.1039/c7cs00877e.
   PubMed Web of Science ®Google Scholar
• Saraf S, Jain A, Tiwari A, et al. Advances in liposomal drug delivery to cancer: an overview. J Drug Delivery Sci Technol. 2020;56:101549. doi: 10.1016/j.jddst.2020.101549.
   Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760. doi: 10.1038/nnano.2007.387.
   PubMed Web of Science ®Google Scholar
• Shi JJ, Xiao ZY, Kamaly N, et al. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc Chem Res. 2011;44(10):1123–1134. doi: 10.1021/ar200054n.
   PubMed Web of Science ®Google Scholar
• Jeong Y, Xie Y, Xiao G, et al. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer. PLoS Med. 2010;7(12):e1000378. doi: 10.1371/journal.pmed.1000378.
   PubMed Web of Science ®Google Scholar
• Holbeck S, Chang J, Best AM, et al. Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor–drug and receptor–gene interactions. Mol Endocrinol. 2010;24(6):1287–1296. doi: 10.1210/me.2010-0040.
   PubMedGoogle Scholar
• Qin Y, Chen H, Yuan W, et al. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm. 2011;419(1–2):85–95. doi: 10.1016/j.ijpharm.2011.07.021.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25. doi: 10.1016/j.addr.2013.11.009.
   PubMed Web of Science ®Google Scholar
• Duncan R, Vicent MJ, Greco F, et al. Polymer–drug conjugates: towards a novel approach for the treatment of endocrine-related cancer. Endocr Relat Cancer. 2005;12(Suppl. 1):S189–S199. doi: 10.1677/erc.1.01045.
   PubMedGoogle Scholar
• Srinivasarao M, Galliford CV, Low PS. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov. 2015;14(3):203–219. doi: 10.1038/nrd4519.
   PubMed Web of Science ®Google Scholar
• Florence AT. "Targeting" nanoparticles: the constraints of physical laws and physical barriers. J Control Release. 2012;164(2):115–124. doi: 10.1016/j.jconrel.2012.03.022.
   PubMed Web of Science ®Google Scholar
• Pirollo KF, Chang EH. Does a targeting ligand influence nanoparticle tumor localization or uptake? Trends Biotechnol. 2008;26(10):552–558. doi: 10.1016/j.tibtech.2008.06.007.
   PubMed Web of Science ®Google Scholar
• Slingerland M, Guchelaar HJ, Rosing H, et al. Bioequivalence of liposome-entrapped paclitaxel easy-to-use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer. Clin Ther. 2013;35(12):1946–1954. doi: 10.1016/j.clinthera.2013.10.009.
   PubMed Web of Science ®Google Scholar
• Awada A, Bondarenko IN, Bonneterre J, et al. A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol. 2014;25(4):824–831. doi: 10.1093/annonc/mdu025.
   PubMed Web of Science ®Google Scholar
• Krauze MT, Noble CO, Kawaguchi T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol. 2007;9(4):393–403. doi: 10.1215/15228517-2007-019.
   PubMed Web of Science ®Google Scholar
• Semple SC, Leone R, Wang J, et al. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci. 2005;94(5):1024–1038. doi: 10.1002/jps.20332.
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Nemunaitis JJ, Malik L, et al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(6):1241–1250. doi: 10.1007/s00280-014-2602-x.
   PubMed Web of Science ®Google Scholar
• Tardi P, Choice E, Masin D, et al. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res. 2000;60(13):3389–3393.
   PubMed Web of Science ®Google Scholar
• Yang SH, Lin CC, Lin ZZ, et al. A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor. Invest New Drugs. 2012;30(1):282–289. doi: 10.1007/s10637-010-9522-3.
   PubMed Web of Science ®Google Scholar
• Leung AK, Tam YY, Cullis PR. Lipid nanoparticles for short interfering RNA delivery. Adv Genet. 2014;88:71–110. doi: 10.1016/B978-0-12-800148-6.00004-3.
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I–II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol. 2001;12(4):493–496. doi: 10.1023/a:1011199028318.
   PubMed Web of Science ®Google Scholar
• Rosenthal DI, Yom SS, Liu L, et al. A phase I study of SPI-077 (stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer. Invest New Drugs. 2002;20(3):343–349. doi: 10.1023/a:1016201732368.
   PubMed Web of Science ®Google Scholar
• Dragovich T, Mendelson D, Kurtin S, et al. A phase 2 trial of the liposomal DACH platinum l-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58(6):759–764. doi: 10.1007/s00280-006-0235-4.
   PubMed Web of Science ®Google Scholar
• Batist G, Gelmon KA, Chi KN, et al. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):692–700. doi: 10.1158/1078-0432.CCR-08-0515.
   PubMed Web of Science ®Google Scholar
• Gamucci T, Paridaens R, Heinrich B, et al. Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: an EORTC-ECSG phase II clinical study. Ann Oncol. 2000;11(7):793–797. doi: 10.1023/a:1008373031714.
   PubMed Web of Science ®Google Scholar
• Seiden MV, Muggia F, Astrow A, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004;93(1):229–232. doi: 10.1016/j.ygyno.2003.12.037.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121(2):234–242. doi: 10.1002/cncr.28974.
   PubMed Web of Science ®Google Scholar
• Boulikas T. Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs. 2009;18(8):1197–1218. doi: 10.1517/13543780903114168.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Antoniou D, Dimitroulis J, et al. Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Ann Oncol. 2010;21(11):2227–2232. doi: 10.1093/annonc/mdq234.
   PubMed Web of Science ®Google Scholar
• Kang MH, Wang J, Makena MR, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21(5):1139–1150. doi: 10.1158/1078-0432.CCR-14-1882.
   PubMed Web of Science ®Google Scholar
• Yarmolenko PS, Zhao Y, Landon C, et al. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia. 2010;26(5):485–498. doi: 10.3109/02656731003789284.
   PubMed Web of Science ®Google Scholar
• Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004;95(7):608–613. doi: 10.1111/j.1349-7006.2004.tb02495.x.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–782. doi: 10.1038/nrd2614.
   PubMed Web of Science ®Google Scholar
• Goodall S, Jones ML, Mahler S. Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy-future prospects. J Chem Technol Biotechnol. 2015;90(7):1169–1176. doi: 10.1002/jctb.4555.
   Web of Science ®Google Scholar
• Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naive, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16(1):352. doi: 10.1186/s12885-016-2385-z.
   PubMedGoogle Scholar
• van der Meel R, Vehmeijer LJ, Kok RJ, et al. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev. 2013;65(10):1284–1298. doi: 10.1016/j.addr.2013.08.012.
   PubMed Web of Science ®Google Scholar
• Birngruber T, Raml R, Gladdines W, et al. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx®/Doxil®—a cerebral open flow microperfusion pilot study. J Pharm Sci. 2014;103(7):1945–1948. doi: 10.1002/jps.23994.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin–PEG-liposome. Int J Pharm. 2008;346(1–2):143–150. doi: 10.1016/j.ijpharm.2007.06.010.
   PubMed Web of Science ®Google Scholar
• Laginha KM, Verwoert S, Charrois GJ, et al. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res. 2005;11(19 Pt 1):6944–6949. doi: 10.1158/1078-0432.CCR-05-0343.
   PubMed Web of Science ®Google Scholar
• Wang RH, Cao HM, Tian ZJ, et al. Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer. Oncol Rep. 2015;33(2):783–791. doi: 10.3892/or.2014.3644.
   PubMed Web of Science ®Google Scholar
• Doolittle E, Peiris PM, Doron G, et al. Spatiotemporal targeting of a dual-ligand nanoparticle to cancer metastasis. ACS Nano. 2015;9(8):8012–8021. doi: 10.1021/acsnano.5b01552.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Lu L, Zhang L, et al. Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide. Sci Rep. 2016;6(1):19800. doi: 10.1038/srep19800.
   PubMedGoogle Scholar
• Qin L, Wang CZ, Fan HJ, et al. A dual-targeting liposome conjugated with transferrin and arginine–glycine–aspartic acid peptide for glioma-targeting therapy. Oncol Lett. 2014;8(5):2000–2006. doi: 10.3892/ol.2014.2449.
   PubMed Web of Science ®Google Scholar
• Kiaie SH, Mojarad-Jabali S, Khaleseh F, et al. Axial pharmaceutical properties of liposome in cancer therapy: recent advances and perspectives. Int J Pharm. 2020;581:119269. doi: 10.1016/j.ijpharm.2020.119269.
   PubMed Web of Science ®Google Scholar
• Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3(1):18496. doi: 10.3402/nano.v3i0.18496.
   PubMedGoogle Scholar
• Fernandez M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci. 2018;9(4):790–810. doi: 10.1039/c7sc04004k.
   PubMed Web of Science ®Google Scholar
• Zhu X, Kong Y, Liu Q, et al. Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Pulm Pharmacol Ther. 2019;55:50–61. doi: 10.1016/j.pupt.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Nguyen VD, Min HK, Kim CS, et al. Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo. Colloids Surf B Biointerfaces. 2019;173:539–548. doi: 10.1016/j.colsurfb.2018.10.013.
   PubMed Web of Science ®Google Scholar
• Silva JD, Fernandes RS, Oda CMR, et al. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model. Biomed Pharmacother. 2019;118:109323. doi: 10.1016/j.biopha.2019.109323.
   PubMed Web of Science ®Google Scholar
• Nunes SS, Miranda SEM, Silva JD, et al. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother. 2021;144:112317. doi: 10.1016/j.biopha.2021.112317.
   PubMed Web of Science ®Google Scholar
• Onodera R, Morioka S, Unida S, et al. Design and evaluation of folate-modified liposomes for pulmonary administration in lung cancer therapy. Eur J Pharm Sci. 2022;168:106081. doi: 10.1016/j.ejps.2021.106081.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Drug Dev Ind Pharm. 2016;42(1):136–149. doi: 10.3109/03639045.2015.1036066.
   PubMed Web of Science ®Google Scholar
• Necela BM, Crozier JA, Andorfer CA, et al. Folate receptor-α (FOLR1) expression and function in triple negative tumors. PLOS One. 2015;10(3):e0122209. doi: 10.1371/journal.pone.0122209.
   PubMed Web of Science ®Google Scholar
• Wang L, Evans JC, Ahmed L, et al. Folate receptor targeted nanoparticles containing niraparib and doxorubicin as a potential candidate for the treatment of high grade serous ovarian cancer. Sci Rep. 2023;13(1):3226. doi: 10.1038/s41598-023-28424-3.
   PubMed Web of Science ®Google Scholar
• Daniels TR, Delgado T, Rodriguez JA, et al. The transferrin receptor. Part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121(2):144–158. doi: 10.1016/j.clim.2006.06.010.
   PubMed Web of Science ®Google Scholar
• Lopalco A, Cutrignelli A, Denora N, et al. Transferrin functionalized liposomes loading dopamine HCl: development and permeability studies across an in vitro model of human blood–brain barrier. Nanomaterials. 2018;8(3):178. doi: 10.3390/nano8030178.
   Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012;1820(3):291–317. doi: 10.1016/j.bbagen.2011.07.016.
   PubMed Web of Science ®Google Scholar
• Sakpakdeejaroen I, Somani S, Laskar P, et al. Transferrin-bearing liposomes entrapping plumbagin for targeted cancer therapy. J Interdiscip Nanomed. 2019;4(2):54–71. doi: 10.1002/jin2.56.
   PubMedGoogle Scholar
• Alsawaftah NM, Awad NS, Paul V, et al. Transferrin-modified liposomes triggered with ultrasound to treat HeLa cells. Sci Rep. 2021;11(1):11589. doi: 10.1038/s41598-021-90349-6.
   PubMed Web of Science ®Google Scholar
• Nandi U, Onyesom I, Douroumis D. Transferrin conjugated stealth liposomes for sirolimus active targeting in breast cancer. J Drug Delivery Sci Technol. 2021;66:102900. doi: 10.1016/j.jddst.2021.102900.
   Web of Science ®Google Scholar
• Fernandes MA, Eloy JO, Luiz MT, et al. Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells. Colloids Surf A Physicochem Eng Asp. 2021;611:125806.
   Web of Science ®Google Scholar
• Jhaveri A, Deshpande P, Pattni B, et al. Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma. J Control Release. 2018;277:89–101. doi: 10.1016/j.jconrel.2018.03.006.
   PubMed Web of Science ®Google Scholar
• Song X-L, Liu S, Jiang Y, et al. Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG2000-transferrin in treatment of brain glioma. Eur J Pharm Sci. 2017;96:129–140. doi: 10.1016/j.ejps.2016.09.024.
   PubMed Web of Science ®Google Scholar
• Heydari M, Gholoobi A, Ranjbar G, et al. Aptamers as potential recognition elements for detection of vitamins and minerals: a systematic and critical review. Crit Rev Clin Lab Sci. 2020;57(2):126–144. doi: 10.1080/10408363.2019.1678566.
   PubMed Web of Science ®Google Scholar
• Xu L, He XY, Liu BY, et al. Aptamer-functionalized albumin-based nanoparticles for targeted drug delivery. Colloids Surf B Biointerfaces. 2018;171:24–30. doi: 10.1016/j.colsurfb.2018.07.008.
   PubMed Web of Science ®Google Scholar
• Yu S, Bi XJ, Yang L, et al. Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo. J Biomed Nanotechnol. 2019;15(6):1135–1148. doi: 10.1166/jbn.2019.2751.
   PubMed Web of Science ®Google Scholar
• Cadinoiu AN, Rata DM, Atanase LI, et al. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polymers. 2019;11(9):1515. doi: 10.3390/polym11091515.
   PubMed Web of Science ®Google Scholar
• Li X, Wu XH, Yang HY, et al. A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer. Biomed Pharmacother. 2019;117:109072. doi: 10.1016/j.biopha.2019.109072.
   PubMed Web of Science ®Google Scholar
• Park H-B, You J-E, Kim P-H, et al. Functionalizing liposomes with dual aptamers for targeting of breast cancer cells and cancer stem cells. Biomed Sci Lett. 2021;27(1):1–11. doi: 10.15616/BSL.2021.27.1.1.
   Google Scholar
• Wu HC, Chang DK. Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J Oncol. 2010;2010:723798. doi: 10.1155/2010/723798.
   PubMedGoogle Scholar
• Zafar S, Beg S, Panda SK, et al. Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems. Semin Cancer Biol. 2021;69:249–267. doi: 10.1016/j.semcancer.2019.08.023.
   PubMed Web of Science ®Google Scholar
• Zhao N, Qin Y, Liu H, et al. Tumor-targeting peptides: ligands for molecular imaging and therapy. Anticancer Agents Med Chem. 2018;18(1):74–86. doi: 10.2174/1871520617666170419143459.
   PubMed Web of Science ®Google Scholar
• Zhang L, Shan X, Meng X, et al. The first integrins beta3-mediated cellular and nuclear targeting therapeutics for prostate cancer. Biomaterials. 2019;223:119471. doi: 10.1016/j.biomaterials.2019.119471.
   PubMed Web of Science ®Google Scholar
• Tang Z, Feng W, Yang Y, et al. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies. Drug Des Devel Ther. 2019;13:3281–3290. doi: 10.2147/DDDT.S211168.
   PubMed Web of Science ®Google Scholar
• D'Avanzo N, Torrieri G, Figueiredo P, et al. LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. Int J Pharm. 2021;597:120346. doi: 10.1016/j.ijpharm.2021.120346.
   PubMed Web of Science ®Google Scholar
• Yan Z, Wang F, Wen Z, et al. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J Control Release. 2012;157(1):118–125. doi: 10.1016/j.jconrel.2011.07.034.
   PubMed Web of Science ®Google Scholar
• Guan J, Guo H, Tang T, et al. iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis. Adv Funct Mater. 2021;31:2100478.
   PubMed Web of Science ®Google Scholar
• Breedveld FC. Therapeutic monoclonal antibodies. Lancet. 2000;355(9205):735–740. doi: 10.1016/s0140-6736(00)01034-5.
   PubMed Web of Science ®Google Scholar
• Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine. 2018;13:3921–3935. doi: 10.2147/IJN.S165210.
   PubMed Web of Science ®Google Scholar
• Gabbia D, Canato E, Carraro V, et al. Novel super stealth immunoliposomes for cancer targeted delivery of doxorubicin: an innovative strategy to reduce liver toxicity. Dig Liver Dis. 2019;51:e21. doi: 10.1016/j.dld.2018.11.073.
   Google Scholar
• Lukyanov AN, Elbayoumi TA, Chakilam AR, et al. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release. 2004;100(1):135–144. doi: 10.1016/j.jconrel.2004.08.007.
   PubMed Web of Science ®Google Scholar
• Khayrani AC, Mahmud H, Oo AKK, et al. Targeting ovarian cancer cells overexpressing CD44 with immunoliposomes encapsulating glycosylated paclitaxel. Int J Mol Sci. 2019;20(5):1042. doi: 10.3390/ijms20051042.
   PubMed Web of Science ®Google Scholar
• Jain S, Deore SV, Ghadi R, et al. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2021;121:111832.
   PubMed Web of Science ®Google Scholar
• Narayanaswamy R, Torchilin VP. Targeted delivery of combination therapeutics using monoclonal antibody 2C5-modified immunoliposomes for cancer therapy. Pharm Res. 2021;38(3):429–450. doi: 10.1007/s11095-021-02986-1.
   PubMed Web of Science ®Google Scholar
• Paliwal SR, Paliwal R, Agrawal GP, et al. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin. J Liposome Res. 2016;26(4):276–287. doi: 10.3109/08982104.2015.1117489.
   PubMed Web of Science ®Google Scholar
• Cosco D, Tsapis N, Nascimento TL, et al. Polysaccharide-coated liposomes by post-insertion of a hyaluronan–lipid conjugate. Colloids Surf B Biointerfaces. 2017;158:119–126. doi: 10.1016/j.colsurfb.2017.06.029.
   PubMed Web of Science ®Google Scholar
• Xu Y, Yao Y, Wang L, et al. Hyaluronic acid coated liposomes co-delivery of natural cyclic peptide RA-XII and mitochondrial targeted photosensitizer for highly selective precise combined treatment of colon cancer. Int J Nanomedicine. 2021;16:4929–4942. doi: 10.2147/IJN.S311577.
   PubMed Web of Science ®Google Scholar
• Gomes IP, Malachias A, Maia ALC, et al. Thermosensitive liposomes containing cisplatin functionalized by hyaluronic acid: preparation and physicochemical characterization. J Nanopart Res. 2022;24(2):30. doi: 10.1007/s11051-021-05352-9.
   Web of Science ®Google Scholar
• Belfiore L. Development of ligand-directed drug-loaded liposomes to target heterogeneous tumour cell populations in metastatic breast cancer [Doctor thesis]. University of Wollongong; 2019.
   Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4(4):297–305. doi: 10.2174/156720107782151269.
   PubMedGoogle Scholar
• Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin Cancer Res. 2004;10(7):2530–2537. doi: 10.1158/1078-0432.ccr-03-0376.
   PubMed Web of Science ®Google Scholar
• Lale SV, Aswathy RG, Aravind A, et al. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy. Biomacromolecules. 2014;15(5):1737–1752. doi: 10.1021/bm5001263.
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhang YY, Yu DM. Lung cancer gene therapy: transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep. 2017;37(2):937–944. doi: 10.3892/or.2016.5298.
   PubMed Web of Science ®Google Scholar
• Kluza E, van der Schaft DW, Hautvast PA, et al. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010;10(1):52–58. doi: 10.1021/nl902659g.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141(2):183–192. doi: 10.1016/j.jconrel.2009.09.020.
   PubMed Web of Science ®Google Scholar
• Sharma G, Modgil A, Zhong T, et al. Influence of short-chain cell-penetrating peptides on transport of doxorubicin encapsulating receptor-targeted liposomes across brain endothelial barrier. Pharm Res. 2014;31(5):1194–1209. doi: 10.1007/s11095-013-1242-x.
   PubMed Web of Science ®Google Scholar
• Rastakhiz S, Yazdani M, Shariat S, et al. Preparation of nanoliposomes linked to HER2/neu-derived (P5) peptide containing MPL adjuvant as vaccine against breast cancer. J Cell Biochem. 2019;120(2):1294–1303. doi: 10.1002/jcb.27090.
   PubMed Web of Science ®Google Scholar
• Samson AAS, Park S, Kim SY, et al. Liposomal co-delivery-based quantitative evaluation of chemosensitivity enhancement in breast cancer stem cells by knockdown of GRP78/CLU. J Liposome Res. 2019;29(1):44–52. doi: 10.1080/08982104.2017.1420081.
   PubMed Web of Science ®Google Scholar
• Farzad N, Barati N, Momtazi-Borojeni AA, et al. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):665–673. doi: 10.1080/21691401.2019.1576702.
   PubMed Web of Science ®Google Scholar
• Sun YQ, Li XQ, Zhang LL, et al. Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer. Mol Pharm. 2019;16(3):1140–1155. doi: 10.1021/acs.molpharmaceut.8b01123.
   PubMed Web of Science ®Google Scholar
• Ju RJ, Cheng L, Qiu X, et al. Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. J Drug Target. 2018;26(9):793–805. doi: 10.1080/1061186X.2018.1428809.
   PubMed Web of Science ®Google Scholar
• Cao DLG, Zhang XX, Akabar M, et al. Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artif Cells Nanomed Biotechnol. 2019;47(1):181–191. doi: 10.1080/21691401.2018.1548470.
   PubMed Web of Science ®Google Scholar
• Vaidya T, Straubinger RM, Ait-Oudhia S. Development and evaluation of tri-functional immunoliposomes for the treatment of HER2 positive breast cancer. Pharm Res. 2018;35(5):95. doi: 10.1007/s11095-018-2365-x.
   PubMed Web of Science ®Google Scholar
• Elamir A, Ajith S, Al Sawaftah N, et al. Ultrasound-triggered herceptin liposomes for breast cancer therapy. Sci Rep. 2021;11(1):7545. doi: 10.1038/s41598-021-86860-5.
   PubMed Web of Science ®Google Scholar
• Belfiore L, Saunders DN, Ranson M, et al. N-alkylisatin-loaded liposomes target the urokinase plasminogen activator system in breast cancer. Pharmaceutics. 2020;12(7):641. doi: 10.3390/pharmaceutics12070641.
   PubMed Web of Science ®Google Scholar
• Li R, Peng Y, Pu YC, et al. Fructose and biotin co-modified liposomes for dual-targeting breast cancer. J Liposome Res. 2022;32(2):119–128. doi: 10.1080/08982104.2021.1894171.
   PubMed Web of Science ®Google Scholar
• Ma JZ, Zhuang HR, Zhuang ZX, et al. Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting. Artif Cells Nanomed Biotechnol. 2018;46:1864–1871.
   PubMed Web of Science ®Google Scholar
• Jin X, Zhou JP, Zhang ZH, et al. The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis. Artif Cells Nanomed Biotechnol. 2018;46(Suppl. 3):S931–S942. doi: 10.1080/21691401.2018.1518913.
   PubMedGoogle Scholar
• Jiang H, Li ZP, Tian GX, et al. Liver-targeted liposomes for codelivery of curcumin and combretastatin A4 phosphate: preparation, characterization, and antitumor effects. Int J Nanomedicine. 2019;14:1789–1804. doi: 10.2147/IJN.S188971.
   PubMed Web of Science ®Google Scholar
• Poy D, Shahemabadi HE, Akbarzadeh A, et al. Carboplatin liposomal nanoparticles: preparation, characterization, and cytotoxicity effects on lung cancer in vitro environment. Int J Polym Mater Polym Biomater. 2018;67(6):367–370. doi: 10.1080/00914037.2017.1332624.
   Web of Science ®Google Scholar
• Yang L, Xin J, Zhang ZH, et al. TPGS-modified liposomes for the delivery of ginsenoside compound K against non-small cell lung cancer: formulation design and its evaluation in vitro and in vivo. J Pharm Pharmacol. 2016;68(9):1109–1118. doi: 10.1111/jphp.12590.
   PubMed Web of Science ®Google Scholar
• Hamzawy MA, Abo-Youssef AM, Salem HF, et al. Antitumor activity of intratracheal inhalation of temozolomide (TMZ) loaded into gold nanoparticles and/or liposomes against urethane-induced lung cancer in BALB/c mice. Drug Deliv. 2017;24(1):599–607. doi: 10.1080/10717544.2016.1247924.
   PubMed Web of Science ®Google Scholar
• Song XL, Ju RJ, Xiao Y, et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2017;12:7433–7451. doi: 10.2147/IJN.S141787.
   PubMed Web of Science ®Google Scholar
• Patel K, Bothiraja C, Mali A, et al. Investigation of sorafenib tosylate loaded liposomal dry powder inhaler for the treatment of non-small cell lung cancer. Part Sci Technol. 2021;39(8):990–999. doi: 10.1080/02726351.2021.1906367.
   Web of Science ®Google Scholar
• Wang SH, Gou JX, Wang Y, et al. Synergistic antitumor efficacy mediated by liposomal co-delivery of polymeric micelles of vinorelbine and cisplatin in non-small cell lung cancer. Int J Nanomedicine. 2021;16:2357–2372. doi: 10.2147/IJN.S290263.
   PubMed Web of Science ®Google Scholar
• Rohilla S, Awasthi R, Mehta M, et al. Preparation and evaluation of gefitinib containing nanoliposomal formulation for lung cancer therapy. BioNanoScience. 2022;12(1):241–255. doi: 10.1007/s12668-022-00938-6.
   Web of Science ®Google Scholar
• Bisht S, Schlesinger M, Rupp A, et al. A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies. J Nanobiotechnology. 2016;14(1):57. doi: 10.1186/s12951-016-0209-6.
   PubMedGoogle Scholar
• Marengo A, Forciniti S, Dando I, et al. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate–copper complex loaded into hyaluronic acid decorated liposomes. Biochim Biophys Acta Gen Subj. 2019;1863(1):61–72. doi: 10.1016/j.bbagen.2018.09.018.
   PubMed Web of Science ®Google Scholar
• Wang YB, Gao FH, Jiang XW, et al. Co-delivery of gemcitabine and mcl-1 SiRNA via cationic liposome-based system enhances the efficacy of chemotherapy in pancreatic cancer. J Biomed Nanotechnol. 2019;15(5):966–978. doi: 10.1166/jbn.2019.2762.
   PubMed Web of Science ®Google Scholar
• Xu HT, Paxton JW, Wu ZM. Development of long-circulating pH-sensitive liposomes to circumvent gemcitabine resistance in pancreatic cancer cells. Pharm Res. 2016;33(7):1628–1637. doi: 10.1007/s11095-016-1902-8.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhang Z. Nanoformulation of apolipoprotein E3-tagged liposomal nanoparticles for the co-delivery of KRAS-siRNA and gemcitabine for pancreatic cancer treatment. Pharm Res. 2020;37(12):247. doi: 10.1007/s11095-020-02949-y.
   PubMed Web of Science ®Google Scholar
• Wei Y, Wang Y, Xia D, et al. Thermosensitive liposomal codelivery of HSA–paclitaxel and HSA–ellagic acid complexes for enhanced drug perfusion and efficacy against pancreatic cancer. ACS Appl Mater Interfaces. 2017;9(30):25138–25151. doi: 10.1021/acsami.7b07132.
   PubMed Web of Science ®Google Scholar
• Le UM, Hartman A, Pillai G. Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells. J Drug Target. 2018;26(8):676–683. doi: 10.1080/1061186X.2017.1408114.
   PubMed Web of Science ®Google Scholar
• Gao J, Nesbitt H, Logan K, et al. An ultrasound responsive microbubble–liposome conjugate for targeted irinotecan-oxaliplatin treatment of pancreatic cancer. Eur J Pharm Biopharm. 2020;157:233–240. doi: 10.1016/j.ejpb.2020.10.012.
   PubMed Web of Science ®Google Scholar
• Iinuma H, Maruyama K, Okinaga K, et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;99(1):130–137. doi: 10.1002/ijc.10242.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004;15(3):517–525. doi: 10.1093/annonc/mdh092.
   PubMed Web of Science ®Google Scholar
• Xiong D, Liu ZB, Bian TR, et al. GX1-mediated anionic liposomes carrying adenoviral vectors for enhanced inhibition of gastric cancer vascular endothelial cells. Int J Pharm. 2015;496(2):699–708. doi: 10.1016/j.ijpharm.2015.11.019.
   PubMedGoogle Scholar
• Hong C, Wang D, Liang J, et al. Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer. Theranostics. 2019;9(15):4437–4449. doi: 10.7150/thno.34953.
   PubMed Web of Science ®Google Scholar
• Yang F, Zheng Z, Zheng L, et al. SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells. Onco Targets Ther. 2018;11:6811–6825. doi: 10.2147/OTT.S182437.
   PubMed Web of Science ®Google Scholar
• Sun YX, Xie YZ, Tang H, et al. In vitro and in vivo evaluation of a novel estrogen-targeted PEGylated oxaliplatin liposome for gastric cancer. Int J Nanomedicine. 2021;16:8279–8303. doi: 10.2147/IJN.S340180.
   PubMed Web of Science ®Google Scholar
• Raza F, Evans L, Motallebi M, et al. Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomater. 2023;157:1–23. doi: 10.1016/j.actbio.2022.12.013.
   PubMed Web of Science ®Google Scholar
• Li H, Li X, Shi X, et al. Effects of magnetic dihydroartemisinin nano-liposome in inhibiting the proliferation of head and neck squamous cell carcinomas. Phytomedicine. 2019;56:215–228. doi: 10.1016/j.phymed.2018.11.007.
   PubMed Web of Science ®Google Scholar
• Lv B-H, Tan W, Shang X, et al. Evaluation of clinical effectiveness of paclitaxel and ursolic acid co-loaded liposomes as enhanced treatment for head and neck squamous cell carcinoma. Trop J Pharm Res. 2019;17(11):2115–2121. doi: 10.4314/tjpr.v17i11.1.
   Web of Science ®Google Scholar
• Wang YP, Liu IJ, Chung MJ, et al. Novel anti-EGFR scFv human antibody-conjugated immunoliposomes enhance chemotherapeutic efficacy in squamous cell carcinoma of head and neck. Oral Oncol. 2020;106:104689. doi: 10.1016/j.oraloncology.2020.104689.
   PubMed Web of Science ®Google Scholar
• Zheng TT, Feng HH, Liu L, et al. Enhanced antiproliferative effect of resveratrol in head and neck squamous cell carcinoma using GE11 peptide conjugated liposome. Int J Mol Med. 2019;43(4):1635–1642. doi: 10.3892/ijmm.2019.4096.
   PubMed Web of Science ®Google Scholar
• Hassanzadeganroudsari M, Heydarinasab A, Khiyavi AA, et al. In vitro investigation of anticancer efficacy of carboplatin-loaded PEGylated nanoliposome particles on brain cancer cell lines. J Nanopart Res. 2019;21(6):124. doi: 10.1007/s11051-019-4562-x.
   Web of Science ®Google Scholar
• Lu YJ, Chuang EY, Cheng YH, et al. Thermosensitive magnetic liposomes for alternating magnetic field-inducible drug delivery in dual targeted brain tumor chemotherapy. Chem Eng J. 2019;373:720–733. doi: 10.1016/j.cej.2019.05.055.
   Web of Science ®Google Scholar
• Perini G, Giulimondi F, Palmieri V, et al. Inhibiting the growth of 3D brain cancer models with bio-coronated liposomal temozolomide. Pharmaceutics. 2021;13(3):378. doi: 10.3390/pharmaceutics13030378.
   PubMed Web of Science ®Google Scholar
• Gabay M, Weizman A, Zeineh N, et al. Liposomal carrier conjugated to APP-derived peptide for brain cancer treatment. Cell Mol Neurobiol. 2021;41(5):1019–1029. doi: 10.1007/s10571-020-00969-1.
   PubMed Web of Science ®Google Scholar
• Petrilli R, Eloy JO, Saggioro FP, et al. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release. 2018;283:151–162. doi: 10.1016/j.jconrel.2018.05.038.
   PubMed Web of Science ®Google Scholar
• Jose A, Labala S, Ninave KM, et al. Effective skin cancer treatment by topical co-delivery of curcumin and STAT3 siRNA using cationic liposomes. AAPS PharmSciTech. 2018;19(1):166–175. doi: 10.1208/s12249-017-0833-y.
   PubMed Web of Science ®Google Scholar
• Hu SC, Su YS, Lai YC, et al. Liposomal avicequinone-B formulations: aqueous solubility, physicochemical properties and apoptotic effects on cutaneous squamous cell carcinoma cells. Phytomedicine. 2019;58:152870. doi: 10.1016/j.phymed.2019.152870.
   PubMed Web of Science ®Google Scholar
• Marwah M, Perrie Y, Badhan RKS, et al. Intracellular uptake of EGCG-loaded deformable controlled release liposomes for skin cancer. J Liposome Res. 2020;30(2):136–149. doi: 10.1080/08982104.2019.1604746.
   PubMed Web of Science ®Google Scholar
• Calienni MN, Febres-Molina C, Llovera RE, et al. Nanoformulation for potential topical delivery of vismodegib in skin cancer treatment. Int J Pharm. 2019;565:108–122. doi: 10.1016/j.ijpharm.2019.05.002.
   PubMed Web of Science ®Google Scholar
• Yin X, Xiao Y, Han L, et al. Ceramide-fabricated co-loaded liposomes for the synergistic treatment of hepatocellular carcinoma. AAPS PharmSciTech. 2018;19(5):2133–2143. doi: 10.1208/s12249-018-1005-4.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhao PX, Wu SP, et al. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. Int J Pharm. 2018;545(1–2):261–273. doi: 10.1016/j.ijpharm.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding RH, Zhang Z, et al. Curcumin-loaded liposomes with the hepatic and lysosomal dual-targeted effects for therapy of hepatocellular carcinoma. Int J Pharm. 2021;602:120628. doi: 10.1016/j.ijpharm.2021.120628.
   PubMedGoogle Scholar
• Qiu F, Zhao X. In vivo antitumor activity of liposome–plasmid DNA encoding mutant survivin-T34A in cervical cancer. Mol Med Rep. 2018;18(1):841–847. doi: 10.3892/mmr.2018.9007.
   PubMed Web of Science ®Google Scholar
• Wang WY, Cao YX, Zhou X, et al. Delivery of folic acid-modified liposomal curcumin for targeted cervical carcinoma therapy. Drug Des Devel Ther. 2019;13:2205–2213. doi: 10.2147/DDDT.S205787.
   PubMed Web of Science ®Google Scholar
• Akhtar A, Ghali L, Wang SX, et al. Optimisation of folate-mediated liposomal encapsulated arsenic trioxide for treating HPV-positive cervical cancer cells in vitro. Int J Mol Sci. 2019;20(9):2156. doi: 10.3390/ijms20092156.
   PubMed Web of Science ®Google Scholar
• Wang SQ, Xu LN, Zhang ZQ, et al. Overexpressed miR-375-loaded restrains development of cervical cancer through down-regulation of frizzled class receptor 4 (FZD4) with liposome nanoparticle as a carrier. J Biomed Nanotechnol. 2021;17(9):1882–1889. doi: 10.1166/jbn.2021.3145.
   PubMed Web of Science ®Google Scholar
• Smith HJ. Tumor treatment using cytokines and cancer drugs. United States patent US 16/926,767. 2022.
   Google Scholar
• Hossann M, Wedmann BC, Lindner LH, et al. Liposome formulations. Germany patent PCT/EP/2021/068568. 2022.
   Google Scholar
• Drummond DC, Geng B, Kirpotin DB, et al. Inhibiting ataxia telangiectasia and Rad3-related protein (ATR). United States patent US 21182826.4. 2022.
   Google Scholar
• Pillarsetty NVK, Larson SM, Lee S-G. Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use. Google Patents. 2022.
   Google Scholar
• Oefelein MG, Venkatesan N, Swarnakar NK, et al. Liposomal enhanced intra-peritoneal chemotherapy. United States patent US 17/290,329. 2022.
   Google Scholar
• Kan P, Tseng Y-L, Han-Chun O, et al. Controlled drug release liposome compositions and methods thereof. Google Patents. 2019.
   Google Scholar
• Vikbjerg AF, Petersen SA, Melander F, et al. Liposomes for drug delivery and methods for preparation thereof. Google Patents. 2021.
   Google Scholar
• Santos A, Frost P. Liposome formulations. Google Patents. 2020.
   Google Scholar
• Moses MA, Guo P, Yang J, et al. Engineered liposomes as cancer-targeted therapeutics. Google Patents. 2022.
   Google Scholar
• Cancedda L, Ben-Ari Y, Constestabile A. Modulators of intracellular chloride concentration for treating down syndrome. United States patent US 2016/0312229 A1. 2017.
   Google Scholar
• Ekdawi SN, Jaffray DA, Allen C. Nanomedicine and tumor heterogeneity: concept and complex reality. Nano Today. 2016;11(4):402–414. doi: 10.1016/j.nantod.2016.06.006.
   Web of Science ®Google Scholar
• Moghimi SM, Farhangrazi ZS. Just so stories: the random acts of anti-cancer nanomedicine performance. Nanomedicine. 2014;10(8):1661–1666. doi: 10.1016/j.nano.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Yan W, Leung SSY, To KKW. Updates on the use of liposomes for active tumor targeting in cancer therapy. Nanomedicine. 2020;15(3):303–318. doi: 10.2217/nnm-2019-0308.
   PubMed Web of Science ®Google Scholar
• Lammers T, Kiessling F, Hennink WE, et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release. 2012;161(2):175–187. doi: 10.1016/j.jconrel.2011.09.063.
   PubMed Web of Science ®Google Scholar
• Fathi S, Oyelere AK. Liposomal drug delivery systems for targeted cancer therapy: is active targeting the best choice? Future Med Chem. 2016;8(17):2091–2112. doi: 10.4155/fmc-2016-0135.
   PubMed Web of Science ®Google Scholar